Evaluation of the efficacy of Socheongryong-tang for improving nasal symptoms in allergic rhinitis patient

Evaluation of the efficacy of Socheongryong-tang for improving nasal symptoms in persistent allergic rhinitis patient : a randomized, cetirizine compared, open-label, pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0002380

Enrollment

Registered

2017-07-20

Start date

2017-07-21

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : The subjects in the experimental group take the Socheongryong-tang orally twice a day for two weeks. The subjects in the control group take the cetirizine orally once a day for two weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Both male and female patients, 19 to 65 years of age 2) Persistent allergic rhinitis patient : Presence of two or more symptoms of allergic rhinitis (rhinorrhea, nasal congestion, nasal itching and sneezing) : Symptoms existing 4 days a week for at least 4 weeks : Persistent allergic rhinitis with a history of at least 2 years, but the symptoms are not controlled by antihistamine treatment : Positive reaction to an allergen in multiple allergen simultaneous test 3) After clearly explaining the purpose and characteristics of this clinical study, participants who voluntarily participated in this clinical study and signed the patient consent form

Exclusion criteria

Exclusion criteria: 1) Those with previous history of nose-related or allergy-related diseases and treatment : Those who have congenital deviated nasal septum, nasal polyps, acute chronic sinusitis, asthma symptoms : Those who have used decongestants, cromolyns within the last 3 days : Those who have taken antihistamines and anticholinergics within the last week. : Those with experience using nasal or oral steroids within 2 weeks : Those who have used leukotriene receptor antagonists in the last 4 weeks : Those who have undergone Korean Medicine (acupucture, moxibustion, herbal medicine, cupping, etc) treatment to treat allergic rhinitis within the past month : Those who have received immunotherapy within the last 5 years 2) Those who are in a serious medical condition to participate in clinical study : Hypertension (systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg) : Diabetes (fasting blood glucose> 126 mg / dL) : Renal dysfunction (serum creatinine level is more than twice the normal range) : Liver function abnormality (AST, ALT value is more than twice the normal range) : Severe condition of hyperlipidemia, anemia, active pulmonary tuberculosis, thyroid disease, other infectious, systematic disease : Those with past or present malignant tumors 3) Pregnancy or breast-feeding 4) Other, If the clinical researcher judges that it is inappropriate : Those who can not use mobile applications to observe symptoms of allergic rhinitis

Design outcomes

Primary

Measure	Time frame
Total nasal symptom score (TNSS)	—

Secondary

Measure	Time frame
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) ;Nasal endoscopy ;Total serum IgE level, eosinophil count;The levels of aspartate aminotransferase (AST) / alanine aminotransferase (ALT), Result of blood urea nitrogen test, creatine blood test	—

Countries

Korea, Republic of

Contacts

Public ContactDong-Hyo Lee

Woosuk University

Outcome results